01
Margin Genome™
- Deal-level erosion ledger
- Service-line margin corridors
- Scope and change trigger library
- Procurement give / get rules
MANDRIXABring a decision ↗Independent commercial decision systems · CROs & CDMOs
Growth is rarely lost in the market.
It leaks between the decisions: quote and delivery, interest and purchase, partnership and profit, pipeline and capacity. Mandrixa finds the leak and changes the commercial rule that created it.
Margin erosionBuyer uncertaintyPartner leakageCapacity misallocation
Alex RickmanCommercial decision architect / Fractional CCO
Start with the economic consequence
Where is value failing to convert?
The framework is not the product. The better commercial decision is.
01The work is winning. The margin is disappearing.
Pricing · scope · change · cash+
Mandrixa response
Margin Genome™
- Reconstruct quoted versus realised contribution
- Separate strategic investment from preventable leakage
- Install price, scope and change-control decision rules
What changes
A deal-level erosion map and the commercial rules that stop the next project repeating it.
02Buyers like the science. The decision still stalls.
Buyer truth · procurement · proof+
Mandrixa response
Buyer Reality Exchange™
- Neutral interviews with buyers, lost deals and procurement
- Internal belief versus external decision-weight analysis
- Proof, packaging and willingness-to-pay corridors
What changes
Independent evidence of what changes the decision — and what merely earns polite interest.
03Partnerships multiply. Incremental revenue does not.
Referrals · co-delivery · client control+
Mandrixa response
Ecosystem Yield & Control™
- Partner-attributed gross-profit reconstruction
- Influence, incrementality and servicing-cost tests
- Customer, data, pricing and relationship-control map
What changes
A defensible decision to invest, renegotiate, repair or exit each material relationship.
04The pipeline is full. The wrong work gets the capacity.
Activation · technical fit · cash velocity+
Mandrixa response
Capacity-to-Cash Conversion™
- Separate award probability from technical activation
- Compare contribution per scarce scientific unit
- Set reservation, expiry and displacement rules
What changes
Capacity allocated to the work most likely to become contribution and cash — not the largest headline deal.
05The symptoms are visible. The commercial constraint is not.
Position · offer · pipeline · economics+
Mandrixa response
Two-Week Commercial Decision Diagnostic
- Read the evidence across six commercial dimensions
- Rank the constraint behind the visible symptoms
- Convert diagnosis into an owned 90-day decision plan
What changes
One executive-grade view of what is actually blocking growth — before money is spent on the wrong remedy.
06The decision is made. It still does not survive execution.
Ownership · governance · cross-functional friction+
Mandrixa response
Commercial Decision Mandate
- Executive decision rights and operating cadence
- Complex-deal and commercial-exception governance
- Board-ready evidence, ownership and movement
What changes
A senior commercial decision layer that remains accountable until the decision changes behaviour.
Four commercial decision systems
Built for evidence your own team cannot grade neutrally.
Each system combines independent evidence, cross-functional challenge and a rule your executive team can continue to use.
02
Buyer Reality Exchange™
- Buyer decision-system map
- Truth Gap heatmap
- No-decision and procurement friction
- Minimum-proof and packaging decision
03
Ecosystem Yield & Control™
- Partner yield / control matrix
- Incrementality and attribution ledger
- Incentive and fee waterfall
- Invest / renegotiate / repair / exit rules
04
Capacity-to-Cash Conversion™
- Contribution per scarce unit
- Award versus activation risk
- Capacity displacement decisions
- Reservation and expiry governance
The Mandrixa method
Do not improve the symptom. Change the decision producing it.
Name the executive decision, its owner and the evidence that would change it.
Rebuild what actually happened across commercial, finance, delivery, quality and the market.
Make the trade-off explicit, confidence-graded and owned at executive level.
Install the rule, decision artefact and review cadence that keeps it moving.
The operating standard
Founder-led commercial decision practice
Independent enough to challenge. Experienced enough to decide.
Mandrixa is led by Alex Rickman, a life-sciences commercial leader experienced in pricing architecture, complex deals, recurring-revenue models and partnership economics.
The work sits where commercial intent collides with procurement, scientific delivery, quality, finance and executive judgement. It is not outsourced lead generation, generic marketing or RevOps.
View Alex on LinkedIn →Bring the decision, not a consultancy brief